Hangzhou Tigermed Consulting Co., Ltd. has declared a final ordinary cash dividend of RMB 1.26 for every 10 shares for the financial year ended 31 December 2025. The distribution is scheduled for payment on 31 July 2026, following shareholder approval at a meeting whose date is yet to be disclosed.

Key timeline details—including the ex-dividend date, record date, book-closure period, default payout currency for the Hong Kong share register, and applicable exchange rate—will be announced in due course. Tricor Investor Services Limited, located at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, will act as share registrar.

The company stated that information on any withholding tax arrangements related to the dividend will be provided when available. No listed warrants or convertible securities are affected by this dividend declaration.

At the time of the announcement (30 March 2026), Tigermed’s board comprises Executive Directors Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu; Independent Non-Executive Directors are Mr. Liu Kai Yu Kenneth, Mr. Yuan Huagang and Ms. Liu Yuwen.